{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:02:37Z","timestamp":1765609357771},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.amjcard.2008.02.027","type":"journal-article","created":{"date-parts":[[2008,4,2]],"date-time":"2008-04-02T12:10:21Z","timestamp":1207138221000},"page":"S9-S13","source":"Crossref","is-referenced-by-count":28,"special_numbering":"S","title":["The Safety of Niacin in the US Food and Drug Administration Adverse Event Reporting Database"],"prefix":"10.1016","volume":"101","author":[{"given":"Alawi A.","family":"Alsheikh-Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H.","family":"Karas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2008.02.027_bib1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.fjc.0000199684.20578.7c","article-title":"High-density lipoprotein cholesterol-raising strategies","volume":"47","author":"Kuvin","year":"2006","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.amjcard.2008.02.027_bib2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/archinte.164.7.697","article-title":"New perspectives on the use of niacin in the treatment of lipid disorders","volume":"164","author":"McKenney","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2008.02.027_bib3","first-page":"III-813","article-title":"Relative safety of extended-release niacin versus other niacin formulations","volume":"110","author":"Alsheikh-Ali","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2008.02.027_bib4","first-page":"II-798","article-title":"Relative safety of lipid altering drugs in the general population","volume":"112","author":"Alsheikh-Ali","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2008.02.027_bib5","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.amjcard.2004.06.033","article-title":"Risk of adverse events with fibrates","volume":"94","author":"Alsheikh-Ali","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2008.02.027_bib6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.amjcard.2007.07.057","article-title":"Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use","volume":"101","author":"Holoshitz","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2008.02.027_bib7","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2008.02.027_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2008.02.027_bib9","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/CIRCULATIONAHA.107.181546","article-title":"Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update","volume":"115","author":"Mosca","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2008.02.027_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.atherosclerosis.2005.01.003","article-title":"High-density lipoprotein cholesterol in the cardiovascular equation: does the \u201cgood\u201d still count?","volume":"180","author":"Alsheikh-Ali","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2008.02.027_bib11","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2008.02.027_bib12","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.amjcard.2007.06.058","article-title":"Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol","volume":"100","author":"Alsheikh-Ali","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2008.02.027_bib13","series-title":"Niaspan [package insert]","year":"2005"},{"key":"10.1016\/j.amjcard.2008.02.027_bib14","series-title":"Zocor [package insert]","year":"2005"},{"issue":"suppl","key":"10.1016\/j.amjcard.2008.02.027_bib15","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am J Cardiol"},{"issue":"suppl","key":"10.1016\/j.amjcard.2008.02.027_bib16","doi-asserted-by":"crossref","first-page":"44K","DOI":"10.1016\/j.amjcard.2005.08.007","article-title":"Pharmacokinetic interactions between statins and fibrates","volume":"96","author":"Corsini","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2008.02.027_bib17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.amjcard.2006.08.044","article-title":"Safety of lovastatin\/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration Adverse Event Reporting System)","volume":"99","author":"Alsheikh-Ali","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2008.02.027_bib18","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.288.13.1588","article-title":"Rates of spontaneous reporting of adverse drug reactions in France","volume":"288","author":"Begaud","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2008.02.027_bib19","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1001\/jama.1983.03330400072029","article-title":"Discovery of adverse drug reactions","volume":"249","author":"Rossi","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2008.02.027_bib20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914908002518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914908002518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,30]],"date-time":"2018-12-30T10:58:12Z","timestamp":1546167492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914908002518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S0002914908002518"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2008.02.027","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}